SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
NEW YORK, Sept. 23, 2016 -- The Nasdaq Stock Market announced today that it will delist the common stock of BIND Therapeutics, Inc. BIND Therapeutics, Inc.’s stock was suspended on August 01, 2016 and has not traded on Nasdaq since that time.
Nasdaq also announced that it will delist the common stock and warrant of InterCloud Systems, Inc. InterCloud Systems, Inc’s common stock and warrant were suspended on August 31, 2016 and have not traded on Nasdaq since that time.
Nasdaq also announced that it will delist the common stock of Echo Therapeutics, Inc. Echo Therapeutics, Inc.’s stock was suspended on July 12, 2016 and has not traded on Nasdaq since that time.
Nasdaq also announced that it will delist the common stock, warrant, unit and right of 1347 Capital Corp. 1347 Capital Corp.’s common stock, warrant, unit and right were suspended on July 12, 2016 and have not traded on Nasdaq since that time.
Finally, Nasdaq announced that it will delist the common stock of EPIRUS Biopharmaceuticals, Inc. EPIRUS Biopharmaceuticals, Inc.’s stock was suspended on August 04, 2016 and has not traded on Nasdaq since that time.
Nasdaq will file a Form 25 with the Securities and Exchange Commission to complete the delisting for each of these companies. The delistings become effective ten days after the Form 25 is filed. For news and additional information about the companies, including the basis for the delistings and whether the companies’ securities are trading on another venue, please review the companies’ public filings or contact the company directly.
For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com. Nasdaq’s rules governing the delisting of securities can be found in the Nasdaq Rule 5800 Series, available on the Nasdaq Web site: http://www.cchwallstreet.com/NasdaqTools/bookmark.asp?id=nasdaq-rule_5800&manual=/nasdaq/main/nasdaq-equityrules/.
NDAQO
